富邦集团控股亚太药业有限公司英文,Introduction

富邦集团控股的亚太药业有限公司的英文名称是 "Zhejiang Yatai Pharmaceutical Co., Ltd."

Introduction

The Chinese pharmaceutical industry has witnessed significant growth over the years, with numerous companies emerging as key players. One such company is Asia Pacific Pharmaceutical Co., Ltd. (亚太药业), which has been under the control of Ningbo Fubang Holding Group Co., Ltd. (富邦集团). This article delves into the relationship between the two entities and the recent developments in their partnership.

About Asia Pacific Pharmaceutical Co., Ltd.

Asia Pacific Pharmaceutical Co., Ltd. (亚太药业), listed on the Shenzhen Stock Exchange under the code 002370.SZ, is a leading pharmaceutical manufacturer in China. The company specializes in the research, development, production, and sales of pharmaceutical products. With a strong focus on the pharmaceutical industry, Asia Pacific Pharmaceutical has established itself as a key player in the market.

About Ningbo Fubang Holding Group Co., Ltd.

Ningbo Fubang Holding Group Co., Ltd. (富邦集团) is a prominent private enterprise in China, with a diverse portfolio of investments across various industries, including pharmaceuticals, real estate, and finance. The group has been instrumental in the growth and development of Asia Pacific Pharmaceutical, providing strategic guidance and financial support.

Recent Share增持 by Fubang Group

In a move to demonstrate confidence in Asia Pacific Pharmaceutical's future prospects and to stabilize the capital market, Fubang Group has been actively增持公司股份. On February 6, 2024, the group announced its intention to purchase shares worth at least 20 million yuan over a period of six months. This commitment was followed by the acquisition of 4,465,400 shares, valued at approximately 13.3 million yuan, representing a 0.73% increase in the company's total share capital.

Completion of Share增持 Plan

As of the date of this article, Fubang Group has successfully completed its share增持计划. The group has accumulated a total of 12,270,000 shares, valued at approximately 36.36 million yuan, which now account for 2.01% of Asia Pacific Pharmaceutical's total share capital. This significant increase in shareholding further solidifies Fubang Group's position as the controlling shareholder of the company.

Financial Performance of Asia Pacific Pharmaceutical

Asia Pacific Pharmaceutical has reported impressive financial performance, with a revenue composition of 99.12% from the pharmaceutical manufacturing sector and 0.88% from other business activities. The company's market value stands at approximately 1.6 billion yuan, reflecting its strong market position and growth potential.

Strategic Importance of the Partnership

The strategic partnership between Asia Pacific Pharmaceutical and Fubang Group is of great importance for both parties. For Asia Pacific Pharmaceutical, the support from Fubang Group has been instrumental in driving the company's growth and development. For Fubang Group, the investment in Asia Pacific Pharmaceutical is a testament to its commitment to the pharmaceutical industry and its belief in the company's long-term prospects.

Conclusion

The relationship between Asia Pacific Pharmaceutical and Fubang Group is a prime example of successful corporate governance and strategic investment. As the pharmaceutical industry continues to evolve, the partnership between these two entities is expected to yield further growth and success. With Fubang Group's continued support and Asia Pacific Pharmaceutical's dedication to innovation and quality, the future looks promising for both parties.